In this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center.

Here are some of the key articles we discussed:

1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”. 

     https://pubmed.ncbi.nlm.nih.gov/36989488/

2. CAR-HEMATOTOX score: 

    https://pubmed.ncbi.nlm.nih.gov/34166502/

3. “How I treat cytopenias after CAR T-cell therapy”.

     https://pubmed.ncbi.nlm.nih.gov/36800563/

4. Immune Effector Cell-Associated HLH-Like Syndrome (ASTCT):

    https://pubmed.ncbi.nlm.nih.gov/36906275/

5. ASTCT consensus grading for CRS and ICANS:

    https://pubmed.ncbi.nlm.nih.gov/30592986/

6. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy:

    https://pubmed.ncbi.nlm.nih.gov/35696759/

7. Modified EASIX score for predicting CRS and neurotoxicity:

    https://pubmed.ncbi.nlm.nih.gov/34432870/